Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Certification | 8 | 2019 | 421 | 2.210 |
Why?
|
Skin Diseases | 14 | 2021 | 1089 | 1.670 |
Why?
|
Dermatology | 6 | 2021 | 914 | 1.420 |
Why?
|
Specialty Boards | 6 | 2019 | 235 | 1.270 |
Why?
|
Skin | 17 | 2022 | 4466 | 0.860 |
Why?
|
Herpes Labialis | 2 | 2020 | 28 | 0.770 |
Why?
|
Antigens, Fungal | 4 | 2010 | 69 | 0.750 |
Why?
|
Cyclobutanes | 2 | 2020 | 57 | 0.750 |
Why?
|
Warts | 4 | 2010 | 66 | 0.740 |
Why?
|
Education, Medical, Continuing | 5 | 2018 | 830 | 0.740 |
Why?
|
Pemphigus | 1 | 2021 | 116 | 0.720 |
Why?
|
Foot Dermatoses | 2 | 2010 | 47 | 0.600 |
Why?
|
Hand Dermatoses | 2 | 2010 | 62 | 0.600 |
Why?
|
Eccrine Glands | 2 | 2013 | 52 | 0.590 |
Why?
|
Hair Follicle | 5 | 2000 | 210 | 0.570 |
Why?
|
Keratinocytes | 5 | 2008 | 792 | 0.560 |
Why?
|
Antigens, Viral | 3 | 2005 | 980 | 0.500 |
Why?
|
Graft vs Host Reaction | 5 | 1998 | 103 | 0.490 |
Why?
|
Skin Neoplasms | 11 | 2018 | 5799 | 0.470 |
Why?
|
Elastic Tissue | 1 | 2014 | 65 | 0.470 |
Why?
|
Acanthoma | 1 | 2013 | 2 | 0.460 |
Why?
|
Self-Assessment | 1 | 2016 | 393 | 0.450 |
Why?
|
Fibroadenoma | 1 | 2013 | 41 | 0.450 |
Why?
|
Immunotherapy | 5 | 2017 | 4642 | 0.440 |
Why?
|
Erythema | 2 | 2005 | 262 | 0.420 |
Why?
|
Eligibility Determination | 1 | 2016 | 419 | 0.410 |
Why?
|
Fluorescent Antibody Technique, Direct | 2 | 2022 | 66 | 0.400 |
Why?
|
Periodic Acid-Schiff Reaction | 1 | 2010 | 16 | 0.360 |
Why?
|
Keratosis | 2 | 2013 | 80 | 0.360 |
Why?
|
Receptors, Fibronectin | 2 | 2000 | 37 | 0.360 |
Why?
|
Erythema Multiforme | 3 | 1999 | 31 | 0.340 |
Why?
|
Onychomycosis | 1 | 2010 | 50 | 0.340 |
Why?
|
Precancerous Conditions | 2 | 2008 | 977 | 0.340 |
Why?
|
Bone Marrow Transplantation | 8 | 1998 | 2693 | 0.340 |
Why?
|
Candida | 3 | 2010 | 173 | 0.320 |
Why?
|
Photosensitivity Disorders | 2 | 2005 | 80 | 0.310 |
Why?
|
Carcinoma in Situ | 4 | 2008 | 796 | 0.300 |
Why?
|
Cystitis, Interstitial | 1 | 2008 | 66 | 0.300 |
Why?
|
Dermatitis | 3 | 2017 | 200 | 0.300 |
Why?
|
Psoriasis | 5 | 2023 | 940 | 0.290 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2008 | 4024 | 0.280 |
Why?
|
Ribonuclease III | 1 | 2009 | 279 | 0.280 |
Why?
|
Skin Diseases, Infectious | 2 | 2001 | 77 | 0.270 |
Why?
|
Paraffin Embedding | 2 | 2012 | 302 | 0.270 |
Why?
|
Cheilitis | 1 | 2006 | 7 | 0.270 |
Why?
|
Lip Neoplasms | 1 | 2006 | 36 | 0.260 |
Why?
|
Mastocytosis | 1 | 2008 | 149 | 0.260 |
Why?
|
Muscle, Smooth | 2 | 2000 | 924 | 0.260 |
Why?
|
Lymphocytes | 5 | 1998 | 2611 | 0.260 |
Why?
|
Biopsy | 12 | 2017 | 6771 | 0.260 |
Why?
|
Leg Dermatoses | 1 | 2005 | 20 | 0.260 |
Why?
|
Mumps virus | 2 | 2005 | 23 | 0.260 |
Why?
|
Calcinosis | 1 | 2014 | 1476 | 0.260 |
Why?
|
Porphyrias | 1 | 2005 | 58 | 0.260 |
Why?
|
Genital Diseases, Male | 1 | 2005 | 83 | 0.250 |
Why?
|
Drug Eruptions | 3 | 2023 | 335 | 0.250 |
Why?
|
Laboratories | 1 | 2008 | 462 | 0.240 |
Why?
|
Cytodiagnosis | 1 | 2008 | 442 | 0.240 |
Why?
|
Genital Diseases, Female | 1 | 2005 | 191 | 0.230 |
Why?
|
Glucagonoma | 1 | 2003 | 14 | 0.230 |
Why?
|
Overweight | 1 | 2014 | 2421 | 0.220 |
Why?
|
Cystectomy | 2 | 2021 | 697 | 0.210 |
Why?
|
Seminal Vesicles | 1 | 2003 | 107 | 0.210 |
Why?
|
Licensure | 2 | 2013 | 128 | 0.210 |
Why?
|
Folliculitis | 1 | 2002 | 25 | 0.200 |
Why?
|
Bartonella Infections | 1 | 2001 | 21 | 0.200 |
Why?
|
Urinary Bladder | 1 | 2008 | 1166 | 0.200 |
Why?
|
Ampulla of Vater | 2 | 2012 | 149 | 0.190 |
Why?
|
Granuloma Annulare | 1 | 2001 | 29 | 0.190 |
Why?
|
Humans | 84 | 2023 | 760613 | 0.190 |
Why?
|
Eczema | 1 | 2023 | 245 | 0.190 |
Why?
|
Mast Cells | 1 | 2008 | 1390 | 0.190 |
Why?
|
Immunohistochemistry | 5 | 2014 | 11070 | 0.180 |
Why?
|
Urinary Bladder Neoplasms | 4 | 2021 | 2275 | 0.180 |
Why?
|
Antifungal Agents | 1 | 2005 | 749 | 0.180 |
Why?
|
Injections, Intralesional | 4 | 2010 | 278 | 0.180 |
Why?
|
Administration, Topical | 3 | 2020 | 697 | 0.180 |
Why?
|
PUVA Therapy | 2 | 2004 | 101 | 0.180 |
Why?
|
Bone Marrow | 2 | 2006 | 2914 | 0.180 |
Why?
|
Cryotherapy | 1 | 2001 | 161 | 0.180 |
Why?
|
Myeloproliferative Disorders | 1 | 2006 | 612 | 0.170 |
Why?
|
Administration, Cutaneous | 1 | 2022 | 713 | 0.170 |
Why?
|
Indicators and Reagents | 1 | 2000 | 461 | 0.170 |
Why?
|
Triazoles | 1 | 2005 | 904 | 0.170 |
Why?
|
Fibronectins | 2 | 2000 | 722 | 0.170 |
Why?
|
Clinical Competence | 4 | 2018 | 4783 | 0.170 |
Why?
|
Exanthema | 1 | 2023 | 504 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 2 | 2012 | 4496 | 0.160 |
Why?
|
Mycosis Fungoides | 1 | 2000 | 168 | 0.150 |
Why?
|
Graft vs Host Disease | 5 | 2004 | 3026 | 0.150 |
Why?
|
Ethical Analysis | 1 | 2018 | 41 | 0.150 |
Why?
|
Lupus Erythematosus, Discoid | 1 | 2018 | 61 | 0.150 |
Why?
|
DNA Mutational Analysis | 1 | 2006 | 4108 | 0.150 |
Why?
|
Middle Aged | 40 | 2021 | 220359 | 0.150 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 1997 | 173 | 0.140 |
Why?
|
Adjuvants, Immunologic | 2 | 2020 | 1039 | 0.140 |
Why?
|
Male | 51 | 2021 | 359718 | 0.140 |
Why?
|
Langerhans Cells | 1 | 1997 | 171 | 0.140 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2418 | 0.140 |
Why?
|
Lymphocyte Subsets | 1 | 1998 | 310 | 0.140 |
Why?
|
MicroRNAs | 2 | 2012 | 3787 | 0.140 |
Why?
|
Mucins | 1 | 2000 | 568 | 0.140 |
Why?
|
Hair | 1 | 2000 | 497 | 0.140 |
Why?
|
Muscle Neoplasms | 1 | 1997 | 133 | 0.140 |
Why?
|
Vitiligo | 1 | 1997 | 98 | 0.130 |
Why?
|
Keratin-17 | 1 | 2016 | 26 | 0.130 |
Why?
|
Dermatitis, Exfoliative | 1 | 1996 | 27 | 0.130 |
Why?
|
Aged, 80 and over | 20 | 2021 | 58980 | 0.130 |
Why?
|
Amyloidosis | 1 | 2003 | 817 | 0.130 |
Why?
|
Cyclosporine | 2 | 1996 | 777 | 0.130 |
Why?
|
Patient Care | 1 | 2021 | 624 | 0.130 |
Why?
|
Adenoma, Sweat Gland | 1 | 1995 | 17 | 0.130 |
Why?
|
Adult | 39 | 2021 | 220007 | 0.130 |
Why?
|
Epidermis | 5 | 2003 | 529 | 0.130 |
Why?
|
Transplantation Chimera | 1 | 1998 | 595 | 0.130 |
Why?
|
Integrins | 1 | 2000 | 839 | 0.130 |
Why?
|
Hepatitis C | 1 | 2005 | 1579 | 0.120 |
Why?
|
Pancreatic Neoplasms | 3 | 2012 | 5349 | 0.120 |
Why?
|
Interleukin-3 | 1 | 1996 | 424 | 0.120 |
Why?
|
Biopsy, Needle | 2 | 2014 | 1630 | 0.120 |
Why?
|
HIV | 1 | 2002 | 1579 | 0.120 |
Why?
|
United States | 9 | 2019 | 72448 | 0.120 |
Why?
|
Lymphomatoid Papulosis | 1 | 1994 | 16 | 0.120 |
Why?
|
Aged | 30 | 2021 | 169143 | 0.120 |
Why?
|
Necrosis | 3 | 2005 | 1612 | 0.110 |
Why?
|
Fee-for-Service Plans | 1 | 1999 | 705 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2020 | 1548 | 0.110 |
Why?
|
Pain | 2 | 2008 | 5066 | 0.110 |
Why?
|
Cytoskeletal Proteins | 1 | 1999 | 1344 | 0.110 |
Why?
|
Pyrimidines | 1 | 2005 | 3016 | 0.110 |
Why?
|
Graves Disease | 1 | 2014 | 239 | 0.110 |
Why?
|
Female | 44 | 2021 | 391246 | 0.110 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 886 | 0.100 |
Why?
|
Pyoderma Gangrenosum | 1 | 2013 | 84 | 0.100 |
Why?
|
Chronic Disease | 6 | 2018 | 9288 | 0.100 |
Why?
|
Retrospective Studies | 14 | 2021 | 80345 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2016 | 8512 | 0.100 |
Why?
|
T-Lymphocytes | 5 | 2000 | 10181 | 0.100 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2017 | 975 | 0.100 |
Why?
|
Common Bile Duct Neoplasms | 1 | 2012 | 120 | 0.100 |
Why?
|
Adenocarcinoma | 3 | 2016 | 6316 | 0.100 |
Why?
|
Nipples | 1 | 2013 | 221 | 0.100 |
Why?
|
Immunoenzyme Techniques | 5 | 2004 | 1705 | 0.090 |
Why?
|
Intercellular Adhesion Molecule-1 | 3 | 2006 | 1126 | 0.090 |
Why?
|
Transforming Growth Factor alpha | 1 | 1991 | 135 | 0.090 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1994 | 662 | 0.090 |
Why?
|
Silver Staining | 1 | 2010 | 63 | 0.090 |
Why?
|
Antineoplastic Agents | 4 | 2002 | 13627 | 0.090 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2010 | 104 | 0.090 |
Why?
|
Autoantibodies | 1 | 1999 | 2119 | 0.090 |
Why?
|
Nephrogenic Fibrosing Dermopathy | 1 | 2010 | 42 | 0.090 |
Why?
|
Breast Diseases | 1 | 2013 | 443 | 0.090 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2010 | 101 | 0.090 |
Why?
|
Cell Count | 2 | 2008 | 1835 | 0.090 |
Why?
|
Educational Measurement | 1 | 2016 | 1248 | 0.080 |
Why?
|
Neoplasm Staging | 5 | 2021 | 11152 | 0.080 |
Why?
|
Rare Diseases | 1 | 2014 | 619 | 0.080 |
Why?
|
Diagnosis, Differential | 6 | 2005 | 12968 | 0.080 |
Why?
|
Adolescent | 14 | 2017 | 87809 | 0.080 |
Why?
|
Mouth Diseases | 2 | 2004 | 238 | 0.080 |
Why?
|
Cell Nucleus | 3 | 2008 | 2907 | 0.080 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 1989 | 85 | 0.080 |
Why?
|
Thyroidectomy | 1 | 2014 | 902 | 0.080 |
Why?
|
Recurrence | 2 | 2020 | 8483 | 0.080 |
Why?
|
Cystoscopy | 1 | 2008 | 133 | 0.080 |
Why?
|
Radiopharmaceuticals | 1 | 1997 | 2634 | 0.070 |
Why?
|
Interferon-gamma | 1 | 1996 | 3157 | 0.070 |
Why?
|
Double-Blind Method | 3 | 2020 | 12427 | 0.070 |
Why?
|
Reagins | 1 | 1987 | 7 | 0.070 |
Why?
|
Pityriasis | 1 | 1987 | 11 | 0.070 |
Why?
|
Treatment Outcome | 9 | 2021 | 64981 | 0.070 |
Why?
|
Communication | 1 | 2021 | 3849 | 0.070 |
Why?
|
Scalp | 2 | 2000 | 389 | 0.070 |
Why?
|
Syphilis Serodiagnosis | 1 | 1987 | 37 | 0.070 |
Why?
|
Program Development | 1 | 2013 | 1297 | 0.070 |
Why?
|
ras Proteins | 1 | 2012 | 1051 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2015 | 39262 | 0.070 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1998 | 1629 | 0.070 |
Why?
|
Trichophyton | 1 | 2005 | 19 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 4356 | 0.070 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 1997 | 2536 | 0.070 |
Why?
|
Cytokines | 2 | 2018 | 7344 | 0.060 |
Why?
|
Restriction Mapping | 1 | 2006 | 852 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 1997 | 2531 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10826 | 0.060 |
Why?
|
HIV Seropositivity | 1 | 1990 | 955 | 0.060 |
Why?
|
Neoplasms, Vascular Tissue | 1 | 2004 | 25 | 0.060 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1469 | 0.060 |
Why?
|
Cytomegalovirus | 1 | 1989 | 755 | 0.060 |
Why?
|
Polymerase Chain Reaction | 2 | 2006 | 6065 | 0.060 |
Why?
|
Cell Adhesion Molecules | 1 | 1991 | 1602 | 0.060 |
Why?
|
Extracellular Matrix | 2 | 2004 | 1726 | 0.060 |
Why?
|
Weight Gain | 1 | 2014 | 2347 | 0.060 |
Why?
|
Thrombomodulin | 1 | 2004 | 105 | 0.060 |
Why?
|
Syphilis | 1 | 1987 | 241 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3612 | 0.060 |
Why?
|
Giant Cells | 1 | 2004 | 185 | 0.060 |
Why?
|
Ichthyosis | 1 | 2003 | 59 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5508 | 0.050 |
Why?
|
Janus Kinase 2 | 1 | 2006 | 542 | 0.050 |
Why?
|
Gadolinium | 1 | 2008 | 959 | 0.050 |
Why?
|
Cytomegalovirus Infections | 1 | 1989 | 831 | 0.050 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2003 | 95 | 0.050 |
Why?
|
Mass Screening | 1 | 1999 | 5422 | 0.050 |
Why?
|
Immunophenotyping | 2 | 1998 | 1870 | 0.050 |
Why?
|
Sirolimus | 1 | 2010 | 1547 | 0.050 |
Why?
|
Curriculum | 1 | 2016 | 3718 | 0.050 |
Why?
|
Mumps | 1 | 2003 | 71 | 0.050 |
Why?
|
Bartonella quintana | 1 | 2001 | 3 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2010 | 14661 | 0.050 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2012 | 2053 | 0.050 |
Why?
|
Germany | 2 | 2015 | 873 | 0.050 |
Why?
|
Bartonella henselae | 1 | 2001 | 15 | 0.050 |
Why?
|
Primary Health Care | 1 | 1999 | 4647 | 0.050 |
Why?
|
Fibrosis | 3 | 2008 | 2042 | 0.050 |
Why?
|
Syndrome | 1 | 2008 | 3280 | 0.050 |
Why?
|
Observer Variation | 1 | 2008 | 2601 | 0.050 |
Why?
|
Tacrolimus | 1 | 2005 | 733 | 0.050 |
Why?
|
Inflammation | 2 | 2018 | 10755 | 0.050 |
Why?
|
Plasma Cells | 2 | 1998 | 591 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2012 | 20080 | 0.050 |
Why?
|
Point Mutation | 1 | 2006 | 1594 | 0.050 |
Why?
|
HIV Infections | 2 | 2002 | 17165 | 0.050 |
Why?
|
Immune Sera | 1 | 2001 | 613 | 0.050 |
Why?
|
Alcian Blue | 1 | 2000 | 13 | 0.050 |
Why?
|
Medicare | 1 | 1999 | 6785 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2006 | 1745 | 0.040 |
Why?
|
Candidiasis | 1 | 2003 | 363 | 0.040 |
Why?
|
Integrin alpha1beta1 | 1 | 2000 | 7 | 0.040 |
Why?
|
Immune Tolerance | 1 | 1989 | 2299 | 0.040 |
Why?
|
Epithelial Cells | 2 | 2006 | 3663 | 0.040 |
Why?
|
Fibroblasts | 1 | 1990 | 4089 | 0.040 |
Why?
|
Culture Techniques | 1 | 2000 | 530 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 1999 | 5890 | 0.040 |
Why?
|
Medical Records | 1 | 2005 | 1407 | 0.040 |
Why?
|
Osteoclasts | 1 | 2004 | 712 | 0.040 |
Why?
|
Child | 9 | 2005 | 79799 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2003 | 11345 | 0.040 |
Why?
|
Erythrocytes | 1 | 1988 | 2415 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2013 | 2942 | 0.040 |
Why?
|
Carcinoma | 1 | 1990 | 2331 | 0.040 |
Why?
|
Desmoplakins | 1 | 1999 | 62 | 0.040 |
Why?
|
Mississippi | 1 | 1999 | 93 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2001 | 616 | 0.040 |
Why?
|
Antibodies | 1 | 1987 | 2421 | 0.040 |
Why?
|
Hidradenitis | 1 | 1998 | 3 | 0.040 |
Why?
|
Contrast Media | 2 | 2010 | 5305 | 0.040 |
Why?
|
Miliaria | 1 | 1998 | 6 | 0.040 |
Why?
|
Sweat Gland Diseases | 1 | 1998 | 12 | 0.040 |
Why?
|
Mice, Inbred MRL lpr | 1 | 2018 | 153 | 0.040 |
Why?
|
Serine Endopeptidases | 1 | 2003 | 1021 | 0.040 |
Why?
|
Dermatitis, Atopic | 1 | 2005 | 716 | 0.040 |
Why?
|
Hypohidrosis | 1 | 1998 | 29 | 0.040 |
Why?
|
Sebaceous Glands | 1 | 1997 | 42 | 0.040 |
Why?
|
Placebos | 2 | 2020 | 1668 | 0.040 |
Why?
|
Hyperhidrosis | 1 | 1998 | 34 | 0.040 |
Why?
|
Sweat | 1 | 1998 | 56 | 0.040 |
Why?
|
Technetium Tc 99m Medronate | 1 | 1997 | 131 | 0.040 |
Why?
|
Blister | 1 | 1998 | 87 | 0.040 |
Why?
|
Coloring Agents | 1 | 2000 | 562 | 0.040 |
Why?
|
Hypopigmentation | 1 | 1997 | 43 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2002 | 857 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2010 | 3759 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2008 | 2093 | 0.040 |
Why?
|
HIV-1 | 1 | 1994 | 6849 | 0.040 |
Why?
|
Electrolytes | 1 | 1998 | 274 | 0.040 |
Why?
|
Y Chromosome | 1 | 1998 | 205 | 0.030 |
Why?
|
Metaplasia | 1 | 1998 | 320 | 0.030 |
Why?
|
Young Adult | 4 | 2017 | 58748 | 0.030 |
Why?
|
Mutation | 2 | 2012 | 29957 | 0.030 |
Why?
|
DNA, Bacterial | 1 | 2001 | 1456 | 0.030 |
Why?
|
American Medical Association | 1 | 2016 | 60 | 0.030 |
Why?
|
DNA Methylation | 1 | 2010 | 4372 | 0.030 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2013 | 2421 | 0.030 |
Why?
|
Leukocyte Count | 2 | 1990 | 1599 | 0.030 |
Why?
|
Exocytosis | 1 | 1997 | 319 | 0.030 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1996 | 176 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2000 | 2471 | 0.030 |
Why?
|
Premedication | 1 | 1996 | 253 | 0.030 |
Why?
|
Proteinuria | 1 | 1999 | 594 | 0.030 |
Why?
|
Conjunctivitis | 1 | 1997 | 155 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 1996 | 6538 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2006 | 5201 | 0.030 |
Why?
|
Cell Differentiation | 3 | 2002 | 11481 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2004 | 1869 | 0.030 |
Why?
|
Antibodies, Monoclonal | 3 | 2000 | 9185 | 0.030 |
Why?
|
Diagnostic Errors | 1 | 2002 | 1266 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2006 | 4716 | 0.030 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 1997 | 209 | 0.030 |
Why?
|
Antigens, CD1 | 1 | 1997 | 439 | 0.030 |
Why?
|
Rats, Inbred ACI | 1 | 1994 | 34 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2006 | 3022 | 0.030 |
Why?
|
Pilot Projects | 2 | 2001 | 8556 | 0.030 |
Why?
|
Acute Disease | 2 | 1998 | 7268 | 0.030 |
Why?
|
Cyclosporins | 1 | 1994 | 216 | 0.030 |
Why?
|
HIV Core Protein p24 | 1 | 1994 | 245 | 0.030 |
Why?
|
Herpesvirus 1, Human | 1 | 2020 | 753 | 0.030 |
Why?
|
Mouth Mucosa | 1 | 1997 | 426 | 0.030 |
Why?
|
Antigens, CD | 2 | 1998 | 4000 | 0.030 |
Why?
|
Connective Tissue Diseases | 1 | 1997 | 286 | 0.030 |
Why?
|
HLA-DR Antigens | 1 | 1996 | 630 | 0.030 |
Why?
|
BCG Vaccine | 1 | 1997 | 371 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 1998 | 1900 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2006 | 2526 | 0.030 |
Why?
|
Coma | 1 | 1998 | 487 | 0.030 |
Why?
|
Prostatectomy | 1 | 2003 | 1956 | 0.030 |
Why?
|
Demography | 1 | 1999 | 1650 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 1998 | 4353 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 1997 | 1975 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15840 | 0.030 |
Why?
|
Fumarates | 1 | 1994 | 131 | 0.030 |
Why?
|
Cytoplasm | 1 | 1998 | 1516 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6544 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2000 | 3094 | 0.030 |
Why?
|
Preoperative Period | 1 | 2015 | 555 | 0.030 |
Why?
|
Phenotype | 2 | 2023 | 16548 | 0.030 |
Why?
|
Interleukin-1 | 1 | 1996 | 1249 | 0.030 |
Why?
|
Virus Activation | 1 | 1994 | 319 | 0.030 |
Why?
|
Physical Examination | 1 | 1999 | 1244 | 0.030 |
Why?
|
Epithelium | 1 | 1997 | 1605 | 0.030 |
Why?
|
Rats, Inbred Lew | 1 | 1994 | 1154 | 0.030 |
Why?
|
Child, Preschool | 3 | 2003 | 42056 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2005 | 4167 | 0.030 |
Why?
|
Eosinophils | 1 | 1997 | 944 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20509 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4899 | 0.020 |
Why?
|
Edema | 1 | 1996 | 770 | 0.020 |
Why?
|
Whole-Body Irradiation | 1 | 1992 | 433 | 0.020 |
Why?
|
Diabetes Complications | 1 | 1999 | 1341 | 0.020 |
Why?
|
Amsacrine | 1 | 1991 | 19 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2017 | 910 | 0.020 |
Why?
|
Drug Resistance | 1 | 2017 | 1617 | 0.020 |
Why?
|
Survival Rate | 2 | 2015 | 12810 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 1996 | 2235 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 1998 | 2897 | 0.020 |
Why?
|
Endocrine System Diseases | 1 | 2013 | 250 | 0.020 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2012 | 1722 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2001 | 2696 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 1999 | 1784 | 0.020 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 1991 | 64 | 0.020 |
Why?
|
Daunorubicin | 1 | 1991 | 155 | 0.020 |
Why?
|
Genome, Viral | 1 | 1994 | 658 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 1998 | 1792 | 0.020 |
Why?
|
Formaldehyde | 1 | 2012 | 358 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 1990 | 6853 | 0.020 |
Why?
|
Metaphase | 1 | 1990 | 144 | 0.020 |
Why?
|
Bilirubin | 1 | 1992 | 438 | 0.020 |
Why?
|
Ploidies | 1 | 1990 | 275 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2931 | 0.020 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 1991 | 377 | 0.020 |
Why?
|
Cytarabine | 1 | 1991 | 696 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 1998 | 2203 | 0.020 |
Why?
|
Histocytochemistry | 1 | 1989 | 700 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 1998 | 1274 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 1996 | 21029 | 0.020 |
Why?
|
Tissue Donors | 1 | 1998 | 2314 | 0.020 |
Why?
|
Endothelium | 1 | 1991 | 764 | 0.020 |
Why?
|
Time Factors | 3 | 2015 | 40139 | 0.020 |
Why?
|
Pancreatectomy | 1 | 2012 | 810 | 0.020 |
Why?
|
Leukemia, Myeloid | 1 | 1991 | 696 | 0.020 |
Why?
|
Bone Marrow Diseases | 1 | 1989 | 233 | 0.020 |
Why?
|
DNA, Viral | 1 | 1994 | 2194 | 0.020 |
Why?
|
Lipids | 1 | 1999 | 3336 | 0.020 |
Why?
|
Prospective Studies | 4 | 2003 | 54306 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3618 | 0.020 |
Why?
|
Ultrasonography | 1 | 2000 | 5961 | 0.020 |
Why?
|
Single-Blind Method | 1 | 1990 | 1578 | 0.020 |
Why?
|
Gadolinium DTPA | 1 | 2010 | 823 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1997 | 2924 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 1998 | 11713 | 0.020 |
Why?
|
RNA, Viral | 1 | 1994 | 2838 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 1998 | 4542 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 1998 | 8552 | 0.020 |
Why?
|
Feces | 1 | 1992 | 1455 | 0.020 |
Why?
|
Ointments | 1 | 2005 | 58 | 0.020 |
Why?
|
Animals | 3 | 2018 | 167960 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 1994 | 4815 | 0.020 |
Why?
|
Pancreas | 1 | 2012 | 1677 | 0.020 |
Why?
|
Palliative Care | 1 | 2021 | 3607 | 0.020 |
Why?
|
Fractures, Bone | 1 | 1997 | 2041 | 0.020 |
Why?
|
Gene Frequency | 1 | 2012 | 3613 | 0.020 |
Why?
|
Prognosis | 3 | 2015 | 29661 | 0.020 |
Why?
|
Pancreatitis | 1 | 2012 | 1100 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2010 | 1557 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 1998 | 4742 | 0.010 |
Why?
|
Lymphoma | 1 | 1994 | 1899 | 0.010 |
Why?
|
Granuloma, Pyogenic | 1 | 2004 | 47 | 0.010 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1728 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 1998 | 4550 | 0.010 |
Why?
|
Autopsy | 1 | 2008 | 1007 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2008 | 2262 | 0.010 |
Why?
|
Quality of Health Care | 1 | 1999 | 4360 | 0.010 |
Why?
|
Cell Division | 1 | 1991 | 4463 | 0.010 |
Why?
|
Blotting, Western | 1 | 1991 | 5039 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 2012 | 12159 | 0.010 |
Why?
|
Phagocytosis | 1 | 1988 | 1535 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2003 | 426 | 0.010 |
Why?
|
T-Lymphocyte Subsets | 1 | 1990 | 1810 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 2004 | 653 | 0.010 |
Why?
|
Blood Vessels | 1 | 2008 | 1112 | 0.010 |
Why?
|
Hemangiosarcoma | 1 | 2004 | 216 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2008 | 15760 | 0.010 |
Why?
|
Kallikreins | 1 | 2003 | 231 | 0.010 |
Why?
|
Sunlight | 1 | 2003 | 337 | 0.010 |
Why?
|
Sarcoma, Kaposi | 1 | 2004 | 376 | 0.010 |
Why?
|
Ossification, Heterotopic | 1 | 2004 | 235 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 1999 | 7475 | 0.010 |
Why?
|
Leukemia | 1 | 1989 | 1523 | 0.010 |
Why?
|
Quality Improvement | 1 | 2016 | 3835 | 0.010 |
Why?
|
Risk Assessment | 1 | 2003 | 24102 | 0.010 |
Why?
|
von Willebrand Factor | 1 | 2004 | 673 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1996 | 3610 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1990 | 5869 | 0.010 |
Why?
|
Adenoma | 1 | 1990 | 2148 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 1998 | 9278 | 0.010 |
Why?
|
Hemangioma | 1 | 2004 | 728 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2010 | 5782 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15286 | 0.010 |
Why?
|
Myelodysplastic Syndromes | 1 | 1988 | 1401 | 0.010 |
Why?
|
Rats | 1 | 1994 | 23709 | 0.010 |
Why?
|
Models, Biological | 1 | 1994 | 9468 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1996 | 11902 | 0.010 |
Why?
|
Genotype | 1 | 2012 | 12957 | 0.010 |
Why?
|
DNA | 1 | 1990 | 7233 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 9406 | 0.010 |
Why?
|
Ifosfamide | 1 | 1996 | 232 | 0.010 |
Why?
|
Liver | 2 | 2008 | 7510 | 0.010 |
Why?
|
Smoking | 1 | 2012 | 9073 | 0.010 |
Why?
|
Etoposide | 1 | 1996 | 630 | 0.010 |
Why?
|
Myocardium | 1 | 2008 | 4700 | 0.010 |
Why?
|
Neoplasms | 2 | 2013 | 22075 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2004 | 1801 | 0.010 |
Why?
|
Flushing | 1 | 1994 | 52 | 0.010 |
Why?
|
Carboplatin | 1 | 1996 | 789 | 0.010 |
Why?
|
Joints | 1 | 1994 | 321 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2004 | 2470 | 0.010 |
Why?
|
Pregnancy | 1 | 2013 | 29746 | 0.010 |
Why?
|
Mice | 1 | 2018 | 81209 | 0.010 |
Why?
|
Hepatic Veins | 1 | 1991 | 112 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2004 | 4214 | 0.000 |
Why?
|
Remission Induction | 1 | 1994 | 2392 | 0.000 |
Why?
|
Drug Combinations | 1 | 1994 | 2025 | 0.000 |
Why?
|
Abdominal Pain | 1 | 1994 | 1063 | 0.000 |
Why?
|
Diarrhea | 1 | 1994 | 1319 | 0.000 |
Why?
|
Staining and Labeling | 1 | 1991 | 1089 | 0.000 |
Why?
|
Quality of Life | 1 | 2004 | 13308 | 0.000 |
Why?
|
Cohort Studies | 1 | 2005 | 41337 | 0.000 |
Why?
|
Disease Progression | 1 | 1997 | 13505 | 0.000 |
Why?
|